Medical device maker EarlySense integrates oximetry monitoring into its bedside system and central display system, winning FDA clearance for the U.S. market.
Massachusetts-based medical device maker EarlySense received FDA clearance for its oximetry-integrated bedside system and central display system to help the clinicians provide a higher level of supervision for post-surgical patients.
"EarlySense is the first in the world to combine contact-free respiratory, cardiac and motion monitoring with oximetry. This means, that for the first time ever, hospitals have the ability to monitor the oxygen saturation of a patient in addition to automatically, continuously and in a contact-free manner, monitor that same patient's vital signs and movement," CEO Avner Halperin said in prepared remarks. "The oximetry component, meant for post-surgical patients who require a higher level of supervision, seamlessly integrates into the existing EarlySense system, including the central display station. The combination of deliverables provides clinicians with a flexible tool to facilitate individualized care plans for optimal clinical outcomes on the medical surgical floors."